Quality of life in congenital, untreated, lifetime isolated growth hormone deficiency

Jorge A R Barbosa, Roberto Salvatori, Carla R P Oliveira, Rossana M C Pereira, Catarine T. Farias, Allan V de O Britto, Natália T. Farias, Amanda Blackford, Manuel H. Aguiar-Oliveira

Research output: Contribution to journalArticle

Abstract

Impaired quality of life (QoL) is commonly described as being associated with growth hormone (GH) deficiency (GHD), and beneficial effects of GH replacement therapy on QoL have been reported. However, most studies examined heterogeneous cohorts of patients GHD of varying etiologies, severities and age of onset. Most of these patients miss other pituitary hormones, whose replacement can also influence QoL. We studied the QoL of a homogeneous cohort of 20 adults with isolated GH deficiency (IGHD) due to the same mutation in the GH-releasing hormone receptor gene (IGHD, 10 men) using the Life Satisfaction Hypopituitarism Module (QLS-H), and compared them with 20 matched controls residing in the same community (CO, 10 men). Additionally, the IGHD group was evaluated after 6 months of treatment with bi-monthly depot GH, and after 12 months from its interruption. There was no difference in the total score of QoL (TSQoL) or in any of the nine categories that composes the questionnaire between IGHD and CO. Similar results were obtained when data were analyzed by sex. GH treatment only increased satisfaction with physical endurance, but did not cause an increase in the TSQoL. We conclude that in this unique population congenital, untreated, lifetime IGHD does not reduce QoL, and treatment with GH for 6 months only causes improvement in satisfaction with physical resistance.

Original languageEnglish (US)
Pages (from-to)894-900
Number of pages7
JournalPsychoneuroendocrinology
Volume34
Issue number6
DOIs
StatePublished - Jul 2009

Fingerprint

Pituitary Dwarfism
Growth Hormone
Quality of Life
Carbon Monoxide
Physical Endurance
Hypopituitarism
Pituitary Hormones
Hormone Replacement Therapy
Age of Onset
Therapeutics
Mutation
Population
Genes

Keywords

  • Brazil
  • GH treatment
  • GHRH receptor mutation
  • Isolated growth hormone deficiency
  • Quality of life

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Endocrine and Autonomic Systems

Cite this

Barbosa, J. A. R., Salvatori, R., Oliveira, C. R. P., Pereira, R. M. C., Farias, C. T., Britto, A. V. D. O., ... Aguiar-Oliveira, M. H. (2009). Quality of life in congenital, untreated, lifetime isolated growth hormone deficiency. Psychoneuroendocrinology, 34(6), 894-900. https://doi.org/10.1016/j.psyneuen.2009.01.001

Quality of life in congenital, untreated, lifetime isolated growth hormone deficiency. / Barbosa, Jorge A R; Salvatori, Roberto; Oliveira, Carla R P; Pereira, Rossana M C; Farias, Catarine T.; Britto, Allan V de O; Farias, Natália T.; Blackford, Amanda; Aguiar-Oliveira, Manuel H.

In: Psychoneuroendocrinology, Vol. 34, No. 6, 07.2009, p. 894-900.

Research output: Contribution to journalArticle

Barbosa, JAR, Salvatori, R, Oliveira, CRP, Pereira, RMC, Farias, CT, Britto, AVDO, Farias, NT, Blackford, A & Aguiar-Oliveira, MH 2009, 'Quality of life in congenital, untreated, lifetime isolated growth hormone deficiency', Psychoneuroendocrinology, vol. 34, no. 6, pp. 894-900. https://doi.org/10.1016/j.psyneuen.2009.01.001
Barbosa, Jorge A R ; Salvatori, Roberto ; Oliveira, Carla R P ; Pereira, Rossana M C ; Farias, Catarine T. ; Britto, Allan V de O ; Farias, Natália T. ; Blackford, Amanda ; Aguiar-Oliveira, Manuel H. / Quality of life in congenital, untreated, lifetime isolated growth hormone deficiency. In: Psychoneuroendocrinology. 2009 ; Vol. 34, No. 6. pp. 894-900.
@article{ae3e1b2fb63d4b9295680a6c24d6cbb5,
title = "Quality of life in congenital, untreated, lifetime isolated growth hormone deficiency",
abstract = "Impaired quality of life (QoL) is commonly described as being associated with growth hormone (GH) deficiency (GHD), and beneficial effects of GH replacement therapy on QoL have been reported. However, most studies examined heterogeneous cohorts of patients GHD of varying etiologies, severities and age of onset. Most of these patients miss other pituitary hormones, whose replacement can also influence QoL. We studied the QoL of a homogeneous cohort of 20 adults with isolated GH deficiency (IGHD) due to the same mutation in the GH-releasing hormone receptor gene (IGHD, 10 men) using the Life Satisfaction Hypopituitarism Module (QLS-H), and compared them with 20 matched controls residing in the same community (CO, 10 men). Additionally, the IGHD group was evaluated after 6 months of treatment with bi-monthly depot GH, and after 12 months from its interruption. There was no difference in the total score of QoL (TSQoL) or in any of the nine categories that composes the questionnaire between IGHD and CO. Similar results were obtained when data were analyzed by sex. GH treatment only increased satisfaction with physical endurance, but did not cause an increase in the TSQoL. We conclude that in this unique population congenital, untreated, lifetime IGHD does not reduce QoL, and treatment with GH for 6 months only causes improvement in satisfaction with physical resistance.",
keywords = "Brazil, GH treatment, GHRH receptor mutation, Isolated growth hormone deficiency, Quality of life",
author = "Barbosa, {Jorge A R} and Roberto Salvatori and Oliveira, {Carla R P} and Pereira, {Rossana M C} and Farias, {Catarine T.} and Britto, {Allan V de O} and Farias, {Nat{\'a}lia T.} and Amanda Blackford and Aguiar-Oliveira, {Manuel H.}",
year = "2009",
month = "7",
doi = "10.1016/j.psyneuen.2009.01.001",
language = "English (US)",
volume = "34",
pages = "894--900",
journal = "Psychoneuroendocrinology",
issn = "0306-4530",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Quality of life in congenital, untreated, lifetime isolated growth hormone deficiency

AU - Barbosa, Jorge A R

AU - Salvatori, Roberto

AU - Oliveira, Carla R P

AU - Pereira, Rossana M C

AU - Farias, Catarine T.

AU - Britto, Allan V de O

AU - Farias, Natália T.

AU - Blackford, Amanda

AU - Aguiar-Oliveira, Manuel H.

PY - 2009/7

Y1 - 2009/7

N2 - Impaired quality of life (QoL) is commonly described as being associated with growth hormone (GH) deficiency (GHD), and beneficial effects of GH replacement therapy on QoL have been reported. However, most studies examined heterogeneous cohorts of patients GHD of varying etiologies, severities and age of onset. Most of these patients miss other pituitary hormones, whose replacement can also influence QoL. We studied the QoL of a homogeneous cohort of 20 adults with isolated GH deficiency (IGHD) due to the same mutation in the GH-releasing hormone receptor gene (IGHD, 10 men) using the Life Satisfaction Hypopituitarism Module (QLS-H), and compared them with 20 matched controls residing in the same community (CO, 10 men). Additionally, the IGHD group was evaluated after 6 months of treatment with bi-monthly depot GH, and after 12 months from its interruption. There was no difference in the total score of QoL (TSQoL) or in any of the nine categories that composes the questionnaire between IGHD and CO. Similar results were obtained when data were analyzed by sex. GH treatment only increased satisfaction with physical endurance, but did not cause an increase in the TSQoL. We conclude that in this unique population congenital, untreated, lifetime IGHD does not reduce QoL, and treatment with GH for 6 months only causes improvement in satisfaction with physical resistance.

AB - Impaired quality of life (QoL) is commonly described as being associated with growth hormone (GH) deficiency (GHD), and beneficial effects of GH replacement therapy on QoL have been reported. However, most studies examined heterogeneous cohorts of patients GHD of varying etiologies, severities and age of onset. Most of these patients miss other pituitary hormones, whose replacement can also influence QoL. We studied the QoL of a homogeneous cohort of 20 adults with isolated GH deficiency (IGHD) due to the same mutation in the GH-releasing hormone receptor gene (IGHD, 10 men) using the Life Satisfaction Hypopituitarism Module (QLS-H), and compared them with 20 matched controls residing in the same community (CO, 10 men). Additionally, the IGHD group was evaluated after 6 months of treatment with bi-monthly depot GH, and after 12 months from its interruption. There was no difference in the total score of QoL (TSQoL) or in any of the nine categories that composes the questionnaire between IGHD and CO. Similar results were obtained when data were analyzed by sex. GH treatment only increased satisfaction with physical endurance, but did not cause an increase in the TSQoL. We conclude that in this unique population congenital, untreated, lifetime IGHD does not reduce QoL, and treatment with GH for 6 months only causes improvement in satisfaction with physical resistance.

KW - Brazil

KW - GH treatment

KW - GHRH receptor mutation

KW - Isolated growth hormone deficiency

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=67349159878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349159878&partnerID=8YFLogxK

U2 - 10.1016/j.psyneuen.2009.01.001

DO - 10.1016/j.psyneuen.2009.01.001

M3 - Article

VL - 34

SP - 894

EP - 900

JO - Psychoneuroendocrinology

JF - Psychoneuroendocrinology

SN - 0306-4530

IS - 6

ER -